[Megaloblastic changes in cervical epithelium associated with oral contraceptives and changes after treatment with folic acid].
OBJECTIVE
To study the influence of oral contraceptives on cervical epithelium, serum and red blood cell folate levels of users and to observe the changes after treatment with folic acid.


METHODS
Morphology of cervical epithelium, serum folate and red blood cell folate levels were studied in 101 women who had used oral contraceptives for over 6 months and 33 intrauterine devices users served as controls, 29 women using oral contraceptives with cervical megaloblastic changes were treated with folic acid (5mg daily) for 3-4 weeks and followed up for observation on morphological changes of cervical epithelium.


RESULTS
The mean nuclear diameter of cervical epithelial cells was larger in the oral contraceptive group than that in the control group (P < 0.001). Megaloblastic changes in cervical epithelium occurred in 29 women in the oral contraceptive group (28.7%). There was significant difference in the occurrence of cervical megaloblastic changes between the two groups (P < 0.01). The level of red blood cell folate was lower in the oral contraceptive group than that in the control group (P < 0.05). There was no difference in serum folate, hemoglobin and neutrophil nuclear index between the two groups (P > 0.05). The mean nuclear diameter of cervical epithelial cells decreased significantly (P < 0.001) and multinuclear and vacuolar changes disappeared after folic acid therapy in 26 women with megaloblastic changes.


CONCLUSIONS
Oral contraceptives reduced folate storage in the body and resulted in megaloblastic changes in cervical epithelium. This condition was improved with folic acid therapy.
Li
X
X
Second Affiliated Hospital of Shanxi Medical College, Taiyuan.
Ran
J
J
Rao
H
H
D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects / Q000473:pathology*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects*; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use*; D005494:Folic Acid Deficiency / Q000139:chemically induced / Q000188:drug therapy; D006801:Humans; D008234:Lynestrenol / Q000009:adverse effects*; D008875:Middle Aged; D009644:Norgestrel / Q000009:adverse effects*
D003277:Contraceptives, Oral, Combined; D009644:Norgestrel; D005492:Folic Acid; D008234:Lynestrenol